McBroom & Associates LLC Buys 4,195 Shares of Axon Enterprise, Inc $AXON

McBroom & Associates LLC grew its stake in Axon Enterprise, Inc (NASDAQ:AXON) by 131.5% during the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 7,384 shares of the biotechnology company’s stock after acquiring an additional 4,195 shares during the quarter. Axon Enterprise accounts for 2.5% of McBroom & Associates LLC’s portfolio, making the stock its 18th biggest holding. McBroom & Associates LLC’s holdings in Axon Enterprise were worth $5,299,000 as of its most recent filing with the Securities and Exchange Commission.

Several other large investors have also bought and sold shares of AXON. Vestor Capital LLC lifted its position in Axon Enterprise by 438,636.3% during the second quarter. Vestor Capital LLC now owns 833,599 shares of the biotechnology company’s stock valued at $690,170,000 after purchasing an additional 833,409 shares during the period. Norges Bank purchased a new stake in Axon Enterprise during the 2nd quarter valued at $637,806,000. McElhenny Sheffield Capital Management LLC purchased a new stake in Axon Enterprise during the 2nd quarter valued at $255,833,000. Vanguard Group Inc. lifted its holdings in shares of Axon Enterprise by 3.5% during the 2nd quarter. Vanguard Group Inc. now owns 8,937,260 shares of the biotechnology company’s stock valued at $7,399,515,000 after buying an additional 305,252 shares during the period. Finally, 1832 Asset Management L.P. boosted its stake in shares of Axon Enterprise by 129.2% in the 2nd quarter. 1832 Asset Management L.P. now owns 536,420 shares of the biotechnology company’s stock worth $444,124,000 after buying an additional 302,420 shares during the last quarter. 79.08% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

AXON has been the subject of a number of recent research reports. Northcoast Research upgraded Axon Enterprise from a “neutral” rating to a “buy” rating and set a $742.00 price target for the company in a research note on Tuesday, January 6th. UBS Group cut their price objective on shares of Axon Enterprise from $840.00 to $610.00 and set a “neutral” rating for the company in a research report on Wednesday, November 5th. Piper Sandler decreased their target price on Axon Enterprise from $893.00 to $753.00 and set an “overweight” rating on the stock in a report on Wednesday, November 5th. The Goldman Sachs Group cut their price target on Axon Enterprise from $940.00 to $800.00 and set a “buy” rating for the company in a report on Wednesday, November 5th. Finally, Cowen reaffirmed a “buy” rating on shares of Axon Enterprise in a research report on Wednesday, November 5th. Fourteen investment analysts have rated the stock with a Buy rating and three have given a Hold rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $805.71.

Axon Enterprise Price Performance

AXON stock opened at $636.04 on Friday. The stock has a market cap of $50.19 billion, a PE ratio of 201.28, a P/E/G ratio of 20.02 and a beta of 1.41. Axon Enterprise, Inc has a 12 month low of $469.24 and a 12 month high of $885.91. The company has a 50-day moving average price of $571.18 and a 200 day moving average price of $682.23. The company has a current ratio of 3.12, a quick ratio of 2.89 and a debt-to-equity ratio of 0.57.

Axon Enterprise (NASDAQ:AXON) last announced its quarterly earnings data on Wednesday, November 5th. The biotechnology company reported $1.17 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.63 by ($0.46). Axon Enterprise had a return on equity of 4.29% and a net margin of 10.05%.The firm had revenue of $710.64 million during the quarter, compared to the consensus estimate of $704.83 million. During the same period in the previous year, the business earned $1.45 EPS. The firm’s revenue for the quarter was up 30.6% on a year-over-year basis. Equities research analysts anticipate that Axon Enterprise, Inc will post 5.8 earnings per share for the current year.

Insider Transactions at Axon Enterprise

In other news, CEO Patrick W. Smith sold 10,000 shares of the business’s stock in a transaction dated Monday, December 8th. The shares were sold at an average price of $551.92, for a total value of $5,519,200.00. Following the completion of the sale, the chief executive officer owned 3,110,997 shares in the company, valued at approximately $1,717,021,464.24. The trade was a 0.32% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, CFO Brittany Bagley sold 2,500 shares of Axon Enterprise stock in a transaction on Monday, November 10th. The shares were sold at an average price of $610.00, for a total value of $1,525,000.00. Following the completion of the transaction, the chief financial officer owned 91,092 shares in the company, valued at $55,566,120. This represents a 2.67% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last quarter, insiders sold 60,540 shares of company stock valued at $34,684,738. Company insiders own 4.40% of the company’s stock.

Axon Enterprise Company Profile

Axon Enterprise, Inc develops technology and weapons systems for public safety and law enforcement agencies, combining hardware, software and cloud services. The company’s hardware portfolio includes conducted energy weapons (commonly known as TASER devices), body-worn cameras and in-car camera systems. Axon pairs these devices with a suite of connected products and accessories designed to capture, store and manage field evidence.

Beyond hardware, Axon operates a subscription-based software platform for digital evidence management, evidence review and records management.